{'fraction_non_alphanumeric': 0.03559870550161812, 'fraction_numerical': 0.00889967637540453, 'mean_word_length': 4.700460829493087, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of TGF-beta and TGF-beta-neutralizing antibody on normal skin fibroblasts and scar-derived fibroblasts.

Transforming growth factor-beta (TGF-beta) is known as an important cytokine for scar formation in wound healing. The purpose of the present study was to investigate the effects of TGF-beta and its neutralizing antibody on normal skin fibroblasts and scar-derived fibroblasts in culture. Endogenous TGF-beta levels were similar in all fibroblasts. Cell proliferation increased when TGF-beta 1 or beta 2 was added to the cultures, and the increase was higher and started at a lower level in the scar-derived fibroblasts (p < 0.05). The increase of fibroblasts was suppressed by the addition of TGF-beta-neutralizing antibody to the cultures, and the suppression rate was higher in the scar-derived cells (p < 0.05). Percentages of the cells in the growth phases of cell cycle decreased in the normal skin fibroblasts (p < 0.05) when TGF-beta-neutralizing antibody was added. Our findings showed that scar-derived fibroblasts and normal skin fibroblasts have a different sensitivity to TGF-beta. Further study is needed on the effect of the neutralizing antibody to the cell counts and cell cycle of scar-derived fibroblasts.